Quick Answer
CalciMedica, Inc. reported Net Income of -$29.56 million for fiscal year 2025.
CalciMedica, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$29.56M -115.8% |
-$13.70M +60.1% |
-$34.36M -339.1% |
-$7.82M +78.2% |
-$35.82M -30.1% |
-$27.53M +25.7% |
| Diluted EPS | -$1.97 -61.5% |
-$1.22 +84.1% |
-$7.66 +93.1% |
-$111.16 -6477.5% |
-$1.69 | — |
| Total Assets | $13.59M -31.3% |
$19.79M +62.4% |
$12.19M +263.8% |
$3.35M -95.2% |
$69.09M -32.1% |
$101.79M +150.4% |
| Cash and Equivalents | $11.52M +45.2% |
$7.93M +43.5% |
$5.53M +316.7% |
$1.33M -90.1% |
$13.36M -60.0% |
$33.42M +110.6% |
| Stockholders Equity | -$6.64M -146.1% |
$14.41M +76.7% |
$8.16M +111.4% |
-$71.30M -11.4% |
-$63.99M -167.5% |
$94.79M +192.1% |
| R&D Expense | $15.23M +5.2% |
$14.48M -8.7% |
$15.86M +89.9% |
$8.35M -55.8% |
$18.90M -9.8% |
$20.96M -31.5% |
| Operating Income | -$23.12M +4.5% |
-$24.20M +36.4% |
-$38.08M -168.3% |
-$14.19M +60.5% |
-$35.95M -20.5% |
-$29.83M +20.5% |
| Shares Outstanding | 15.44M +14.5% |
13.48M +134.3% |
5.75M +6737.2% |
84,165 -99.6% |
21.36M +1.8% |
20.98M +1429.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$7.80M | -38.9% | -31.0% |
| Diluted EPS | September 30, 2025 | -$0.52 | -4.0% | -30.0% |
| Total Assets | September 30, 2025 | $14.91M | -8.0% | -21.8% |
| Cash and Equivalents | September 30, 2025 | $5.47M | -40.2% | -7.6% |
| Stockholders Equity | September 30, 2025 | -$268.0K | -103.0% | -104.4% |
| R&D Expense | September 30, 2025 | $3.85M | +8.6% | -5.0% |
| Operating Income | September 30, 2025 | -$5.62M | +2.1% | +15.1% |
| Shares Outstanding | September 30, 2025 | 14.26M | +32.5% | +2.0% |
- CalciMedica, Inc. reported Net Income of -$29.56 million for fiscal year 2025.
- CalciMedica, Inc. showed a decrease of -115.8% in Net Income compared to the prior fiscal year.
- CalciMedica, Inc. reported Diluted EPS of $1.97 per share (loss) for fiscal year 2025.
- CalciMedica, Inc. showed a decrease of -61.5% in Diluted EPS compared to the prior fiscal year.
- CalciMedica, Inc. reported Total Assets of $13.59 million for fiscal year 2025.
- CalciMedica, Inc. showed a decrease of -31.3% in Total Assets compared to the prior fiscal year.
- CalciMedica, Inc. reported Cash and Equivalents of $11.52 million for fiscal year 2025.
- CalciMedica, Inc. showed an increase of +45.2% in Cash and Equivalents compared to the prior fiscal year.
- CalciMedica, Inc. reported Stockholders Equity of -$6.64 million for fiscal year 2025.
- CalciMedica, Inc. showed a decrease of -146.1% in Stockholders Equity compared to the prior fiscal year.
- CalciMedica, Inc. reported R&D Expense of $15.23 million for fiscal year 2025.
- CalciMedica, Inc. showed an increase of +5.2% in R&D Expense compared to the prior fiscal year.
- CalciMedica, Inc. reported Operating Income of -$23.12 million for fiscal year 2025.
- CalciMedica, Inc. showed an increase of +4.5% in Operating Income compared to the prior fiscal year.
- CalciMedica, Inc. reported Shares Outstanding of 15.44 million shares for fiscal year 2025.
- CalciMedica, Inc. showed an increase of +14.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: